Voyager Therapeutics Book Value Per Share Growth & History (VYGR)
Voyager Therapeutics's book value per share was $3.32 for fiscal 2025.
View full Voyager Therapeutics company overviewVoyager Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.32 | -$2.16 | −39.37% |
| 2024 | 2024-12-31 | $5.48 | $0.11 | +2.06% |
| 2023 | 2023-12-31 | $5.37 | $3.84 | +251.09% |
| 2022 | 2022-12-31 | $1.53 | -$0.98 | −39.03% |
| 2021 | 2021-12-31 | $2.51 | -$1.62 | −39.30% |
| 2020 | 2020-12-31 | $4.13 | $1.43 | +52.99% |
| 2019 | 2019-12-31 | $2.70 | $1.26 | +88.10% |
| 2018 | 2018-12-31 | $1.44 | -$2.81 | −66.20% |
| 2017 | 2017-12-31 | $4.25 | -$1.06 | −20.04% |
| 2016 | 2016-12-31 | $5.31 | -$1.47 | −21.70% |
| 2015 | 2015-12-31 | $6.78 | $32.35 | — |
| 2014 | 2014-12-31 | -$25.56 | — | — |
Voyager Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.52 | -$1.88 | −42.75% |
| Q1 2026 | 2026-03-31 | $2.88 | -$2.06 | −41.70% |
| Q4 2025 | 2025-12-31 | $3.32 | -$2.16 | −39.37% |
| Q3 2025 | 2025-09-30 | $3.96 | -$2.09 | −34.58% |
| Q2 2025 | 2025-06-30 | $4.40 | -$1.76 | −28.53% |
| Q1 2025 | 2025-03-31 | $4.94 | -$1.34 | −21.29% |
| Q4 2024 | 2024-12-31 | $5.48 | $0.11 | +2.06% |
| Q3 2024 | 2024-09-30 | $6.06 | $2.04 | +50.90% |
| Q2 2024 | 2024-06-30 | $6.16 | $1.61 | +35.39% |
| Q1 2024 | 2024-03-31 | $6.28 | $1.28 | +25.64% |
| Q4 2023 | 2023-12-31 | $5.37 | $3.84 | +251.09% |
| Q3 2023 | 2023-09-30 | $4.01 | $1.94 | +93.67% |
| Q2 2023 | 2023-06-30 | $4.55 | $2.99 | +191.13% |
| Q1 2023 | 2023-03-31 | $4.99 | $3.01 | +151.57% |
| Q4 2022 | 2022-12-31 | $1.53 | -$0.98 | −39.03% |
| Q3 2022 | 2022-09-30 | $2.07 | -$0.24 | −10.44% |
| Q2 2022 | 2022-06-30 | $1.56 | -$1.36 | −46.62% |
| Q1 2022 | 2022-03-31 | $1.99 | -$1.64 | −45.25% |
| Q4 2021 | 2021-12-31 | $2.51 | -$1.62 | −39.30% |
| Q3 2021 | 2021-09-30 | $2.31 | -$2.15 | −48.13% |
| Q2 2021 | 2021-06-30 | $2.93 | $0.86 | +41.61% |
| Q1 2021 | 2021-03-31 | $3.63 | $1.47 | +68.14% |
| Q4 2020 | 2020-12-31 | $4.13 | $1.43 | +52.99% |
| Q3 2020 | 2020-09-30 | $4.46 | $1.52 | +51.91% |
| Q2 2020 | 2020-06-30 | $2.07 | -$1.16 | −35.98% |
| Q1 2020 | 2020-03-31 | $2.16 | -$0.60 | −21.65% |
| Q4 2019 | 2019-12-31 | $2.70 | $1.26 | +88.10% |
| Q3 2019 | 2019-09-30 | $2.94 | $0.91 | +44.67% |
| Q2 2019 | 2019-06-30 | $3.23 | $0.67 | +26.27% |
| Q1 2019 | 2019-03-31 | $2.75 | -$0.33 | −10.68% |
| Q4 2018 | 2018-12-31 | $1.44 | -$2.81 | −66.20% |
| Q3 2018 | 2018-09-30 | $2.03 | -$1.22 | −37.46% |
| Q2 2018 | 2018-06-30 | $2.56 | -$1.49 | −36.86% |
| Q1 2018 | 2018-03-31 | $3.08 | -$1.66 | −35.06% |
| Q4 2017 | 2017-12-31 | $4.25 | -$1.06 | −20.04% |
| Q3 2017 | 2017-09-30 | $3.25 | -$2.62 | −44.67% |
| Q2 2017 | 2017-06-30 | $4.05 | -$2.11 | −34.27% |
| Q1 2017 | 2017-03-31 | $4.75 | -$1.77 | −27.11% |
| Q4 2016 | 2016-12-31 | $5.31 | -$1.47 | −21.70% |
| Q3 2016 | 2016-09-30 | $5.87 | $40.28 | — |
| Q2 2016 | 2016-06-30 | $6.16 | — | — |
| Q1 2016 | 2016-03-31 | $6.51 | — | — |
| Q4 2015 | 2015-12-31 | $6.78 | $32.35 | — |
| Q3 2015 | 2015-09-30 | -$34.42 | — | — |
| Q4 2014 | 2014-12-31 | -$25.56 | — | — |
Voyager Therapeutics book value per share trends
Over the last five fiscal years, Voyager Therapeutics's book value per share decreased from $4.13 to $3.32, a change of -$0.81. The latest reported quarter, Q2 2026, shows $2.52.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Voyager Therapeutics source filings ↗